Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firuglipel - Daiichi Sankyo Company

Next Previous
Drug Profile

Firuglipel - Daiichi Sankyo Company

Alternative Names: DS-8500; DS-8500a

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics; Benzamides; Cyclopropanes; Fluorobenzenes; Oxadiazoles; Phenyl ethers; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Canada (PO) (Daiichi Sankyo Company pipeline, September 2021)
  • 11 Sep 2017 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 May 2017 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top